Günday Murat, Bingöl Hakan
Department of Cardiovascular Surgery, Ankara Çankaya Hospital, Aşağı Dikmen mah, 575 sok, Orankent konutları B blok No:12, OR-AN Çankaya, Ankara, Turkey.
J Cardiothorac Surg. 2014 Jan 27;9:23. doi: 10.1186/1749-8090-9-23.
Complications due to hemodilution (hematocrit value less than 22%) after cardiopulmonary bypass inevitably resulted with significantly greater intensive care requirements, long hospital stays, more operative costs, and increased mortality rates. We tried to identify whether crystalloid cardioplegia is the strongest predictor of intraoperative hemodilution or not.
One hundred patients were included into this randomized prospective study. Patients were divided into the two groups. Crystalloid cardioplegia were given to the odd-numbered patients (Group 1, n=50 patients) and blood cardioplegia were given to the even-numbered patients (Group 2, n=50 patients). St. Thomas-II solution was used in Group-1 and Calafiore cold blood cardioplegia was in Group-2.
Average intraoperative hematocrit value was 18.4% ± 2.3 in crystalloid group 24.2% ± 3.4 in blood cardioplegia group (p<0.001). The lowest hematocrit value was 15% and 20% in two groups respectively (p<0.001). In crystalloid group average intraoperative packed red blood cell (RBC) transfusion was 2.3 ± 0.41 units, 0.7 ± 0.6 units blood cardioplegia group (p=0.001). Average transfused RBC was 2.7 ± 0.8 units in crystalloid group, 0.9 ± 0.4 units blood cardioplegia group (p<0.001). Multivariate analyses confirmed age (p = 0.005, OR = 3.78), female gender (p = 0.003, OR = 2.91), longer cross-clamp time (>60 minutes) (p = 0.001, OD = 0.97), body surface area <1.6 m2 (p = 0.001, OR = 6.01) and crystalloid cardioplegia (p < 0.001, OR = 0.19) as predictor of intraoperative hemodilution.
Crystalloid cardioplegia, compared to blood cardioplegia not only causes much more intra-operative hemodilution but also increases the blood transfusion requirement. Hemodilution and increased transfusion increases the intensive care unit and hospital stay, in the early postoperative period.
体外循环后因血液稀释(血细胞比容值低于22%)导致的并发症不可避免地带来了显著更高的重症监护需求、更长的住院时间、更高的手术成本以及更高的死亡率。我们试图确定晶体心脏停搏液是否是术中血液稀释的最强预测因素。
100例患者纳入这项随机前瞻性研究。患者被分为两组。奇数编号的患者给予晶体心脏停搏液(第1组,n = 50例患者),偶数编号的患者给予血液心脏停搏液(第2组,n = 50例患者)。第1组使用圣托马斯-II溶液,第2组使用卡拉菲奥雷冷血心脏停搏液。
晶体组术中平均血细胞比容值为18.4%±2.3,血液心脏停搏液组为24.2%±3.4(p<0.001)。两组最低血细胞比容值分别为15%和20%(p<0.001)。晶体组术中平均浓缩红细胞(RBC)输注量为2.3±0.41单位,血液心脏停搏液组为0.7±0.6单位(p = 0.001)。晶体组平均输注RBC为2.7±0.8单位,血液心脏停搏液组为0.9±0.4单位(p<0.001)。多因素分析证实年龄(p = 0.005,OR = 3.78)、女性(p = 0.003,OR = 2.91)、较长的阻断时间(>60分钟)(p = 0.001,OD = 0.97)、体表面积<1.6 m²(p = 0.001,OR = 6.01)以及晶体心脏停搏液(p<0.001,OR = 0.19)是术中血液稀释的预测因素。
与血液心脏停搏液相比,晶体心脏停搏液不仅会导致更多的术中血液稀释,还会增加输血需求。血液稀释和输血增加会导致术后早期重症监护病房停留时间和住院时间延长。